AbCellera Biologics Inc [NASDAQ: ABCL] stock went on an upward path that rose over 1.75% on Tuesday, amounting to a one-week price decrease of less than -5.16%.
Over the last 12 months, ABCL stock rose by 19.11%. The one-year AbCellera Biologics Inc stock forecast points to a potential downside of -63265206.12. The average equity rating for ABCL stock is currently 1.25, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.04 billion, with 298.36 million shares outstanding and 223.95 million shares in the current float. Compared to the average trading volume of 5.27M shares, ABCL stock reached a trading volume of 7506399 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on AbCellera Biologics Inc [ABCL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABCL shares is $8.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABCL stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Benchmark Company have made an estimate for AbCellera Biologics Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on August 20, 2024. The new note on the price target was released on February 22, 2024, representing the official price target for AbCellera Biologics Inc stock. Previously, the target price had yet another raise to $6, while KeyBanc Capital Markets analysts kept a Overweight rating on ABCL stock.
The Price to Book ratio for the last quarter was 1.02, with the Price to Cash per share for the same quarter was set at 2.11.
ABCL Stock Performance Analysis:
AbCellera Biologics Inc [ABCL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.16. With this latest performance, ABCL shares gained by 72.77% in over the last four-week period, additionally plugging by 15.18% over the last 6 months – not to mention a rise of 19.11% in the past year of trading.
Insight into AbCellera Biologics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and AbCellera Biologics Inc [ABCL] shares currently have an operating margin of -1395.34% and a Gross Margin at -318.94%. AbCellera Biologics Inc’s Net Margin is presently recorded at -726.23%.
Return on Equity for this stock declined to -11.96%, with Return on Assets sitting at -11.96%.
ABCL Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABCL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbCellera Biologics Inc go to 0.83%.
AbCellera Biologics Inc [ABCL] Institutonal Ownership Details
There are presently around $44.79%, or 58.14%% of ABCL stock, in the hands of institutional investors. The top three institutional holders of ABCL stocks are: BAKER BROS. ADVISORS LP with ownership of 27.53 million shares, which is approximately 9.3556%. BAILLIE GIFFORD & CO, holding 21.91 million shares of the stock with an approximate value of $$64.86 million in ABCL stocks shares; and BAILLIE GIFFORD & CO, currently with $$31.45 million in ABCL stock with ownership which is approximately 3.611%.
